Key Highlights
• Teradyne (NASDAQ: TER) is rebounding sharply after shedding roughly 14% last week, including a 13.63% single-session drop on July 2.
• Goldman Sachs raised its target to $465 from $350, and BofA maintained a $525 Buy target, both citing an expanded AI-driven total addressable market.
• Q1 2026 revenue hit a record $1.28 billion, up 87% year over year, supported by growing AI chip testing demand via the UltraFLEXplus platform.
Teradyne is surging today as semiconductor stocks rebound sharply, recovering from what had been a brutal stretch for the stock just days earlier. The rebound highlights the volatility that has characterized chip names through the AI infrastructure demand debate.
The rally follows a week that saw Teradyne shed roughly 14%, including a 13.63% single-session drop on July 2, amid broader chip sector fears that AI hyperscalers like Meta were monetizing excess compute capacity, a signal some investors interpreted as pointing to potential demand softness ahead.
Goldman Sachs responded to the rebound by raising its price target to $465 from $350, while Bank of America maintained a Buy rating with a $525 target. Both firms cited an expanded total addressable market outlook driven by AI and data center testing demand as the basis for their continued optimism.
Investors are now recalibrating their view of the prior week's selloff, with Wall Street analysts increasingly framing the pullback as a buying opportunity rather than a signal of deteriorating fundamentals. That reassessment is supported by Teradyne's record first-quarter 2026 results, which showed revenue of $1.28 billion, up 87% year over year.
Teradyne's growing role in AI chip testing, particularly through its UltraFLEXplus platform, positions the company to continue benefiting from AI infrastructure buildout even if near-term sentiment around hyperscaler capital spending remains volatile.
Looking ahead, investors will be watching whether Teradyne can sustain this rebound through the broader second-quarter earnings season, particularly as more hyperscalers report capital spending plans that could either reinforce or undercut the AI demand narrative currently supporting the stock's recovery.
Options traders have also taken note of Teradyne's elevated implied volatility following last week's swings, a signal that the market continues to price in a wide range of potential outcomes as the AI capacity debate plays out over the coming weeks.






Please wait processing your request...